SC
REGN icon

Skylands Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Skylands Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,065
Closed -$1.16M – 157
2025
Q3 		$1.16M Buy
+2,065
New +$1.17M 0.16% 99

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Skylands Capital's REGN Position: Q4 2025 in Review

Skylands Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 2,065 shares — an estimated $1.16M sold.

Skylands Capital first reported a position in REGN in Q3 2025 and held it in 1 quarter. The position peaked at $1.16M in Q3 2025. 1,386 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Skylands Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Skylands Capital sold 2,065 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $1.16M.
  • Skylands Capital first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Skylands Capital's Regeneron Pharmaceuticals position peaked at $1.16M in Q3 2025.
  • 1,386 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Skylands Capital's 13F filing for Q4 2025, filed 30 Jan 2026.